英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
divulgatio查看　divulgatio　在百度字典中的解释百度英翻中〔查看〕
divulgatio查看　divulgatio　在Google字典中的解释Google英翻中〔查看〕
divulgatio查看　divulgatio　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
    Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements See safety info including Boxed Warning
  • Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) extended . . .
    AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia
  • Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
    Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor) Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once daily What is Tardive dyskinesia (TD) and chorea associated with Huntington’s disease
  • AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine . . .
    The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets
  • Real-world data shows AUSTEDO improves life for patients with tardive . . .
    Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (extended-release) tablets led to meaningful improvements for adults living with tardive dyskinesia (TD) The findings were presented at the 2025 Neuroscience Education Institute Fall Congress
  • Teva Pharmaceuticals Reports Positive Real-World Data on AUSTEDO and . . .
    Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of adults with tardive dyskinesia (TD) In a cohort of 27 participants, up to 77% reported enhancements in daily activities such as speech and eating after three months of treatment
  • Austedo for Uncontrolled Movements in Huntington’s and Tardive Dyskinesia
    Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease
  • Dosing for Tardive Dyskinesia | AUSTEDO XR® (deutetrabenazine)
    Learn about once-daily dosages for AUSTEDO XR® (deutetrabenazine) extended release tablets for Tardive Dyskinesia (TD) See safety info and Boxed Warning
  • What is the treatment for Tardive Dyskinesia (TD)?
    The efficacy of AUSTEDO in the treatment for tardive dyskinesia was established in two 12‑week, randomized, double-blind, placebo-controlled, multi-center trials conducted in 335 adult ambulatory patients with tardive dyskinesia caused by use of dopamine receptor antagonists The Abnormal Involuntary Movement Scale (AIMS) was the primary
  • Austedo XR: FDA Approved for tardive Dyskinesia
    In a significant advancement for those suffering from tardive dyskinesia (TD), the U S Food and Drug Administration (FDA) recently approved Austedo XR (extended-release deutetrabenazine) This approval brings a new, convenient treatment option for patients grappling with this often debilitating condition The most notable advantage of Austedo XR is its once-daily dosing regimen This is a





中文字典-英文字典  2005-2009